Abeona Therapeutics ABEO 深 滬
等待開盤 10-22 09:30:00 美东时间
5.50
0.000
0.00%
華盛通- 最 高5.575
- 今 開5.51
- 成交量 46.03万股
- 最 低 5.36
- 昨 收 5.50
- 總市值 2.82亿
- 52周最高 7.5401
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 3.9328
- 委 比 -61.55%
- 總股本 5127.85万
- 歷史最高 750.00
- 量 比 0.65
- 振 幅 3.91%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
Abeona Therapeutics announced the appointment of Dr. James A. Gow as Senior Vice President, Head of Clinical Development & Medical Affairs. With over 20 years of experience in gene therapy, particularly in ophthalmology, Dr. Gow has successfully led multiple FDA-approved programs. He joins Abeona as it advances cell and gene therapies for serious diseases, including ZEVASKYN for recessive dystrophic epidermolysis bullosa.
10-20 12:30
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
10-13 19:18
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
Abeona Therapeutics' ABO-503 gene therapy for X-linked retinoschisis (XLRS) has been selected for the FDA's RDEA Pilot Program, designed to advance rare disease treatments by supporting novel efficacy endpoints. XLRS, a rare genetic retinal disorder causing severe vision loss, currently has no approved therapies. ABO-503, utilizing a functional RS1 gene delivered via a novel AAV capsid, has shown promising preclinical results, including improved ...
10-13 11:30
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
<p>Abeona Therapeutics and Children's Hospital Colorado have activated the hospital as a Qualified Treatment Center (QTC) for ZEVASKYN, the first gene therapy approved for treating wounds in adults and children with recessive dystrophic epidermolysis bullosa (RDEB). The therapy involves gene-modified skin cells to produce functional type VII collagen, addressing the genetic defect causing the disease. Children's Colorado, recognized as a center o...
10-08 11:30
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics Inc. announced that its management team will participate in two upcoming investor conferences in September 2025: a fireside chat at the Cantor Global Healthcare Conference on September 4 and a presentation at the H.C. Wainwright Global Investment Conference on September 9. Both events will be webcast live and available for replay on the company’s website. Abeona, a biopharmaceutical company, develops cell and gene therapies fo...
08-29 11:30
Krystal Biotech adjusts pipeline to prioritize inhaled antitumor agent
Krystal Biotech (NASDAQ:KRYS) announced Thursday a revamped product pipeline after a decision to prioritize studies for an inhaled version of its antitumor candidate KB707 targeted at non-small cell l...
08-22 00:59
Oppenheimer Maintains Outperform on Abeona Therapeutics, Raises Price Target to $20
Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and raises the price target from $19 to $20.
08-15 22:35
快讯 | Abeona Therapeutics, Inc.：Oppenheimer 将目标价从 19 美元上调至 20 美元
Abeona Therapeutics, Inc. : Oppenheimer Raises Target Price to $20 From $19
08-15 20:12
Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Abeona Therapeutics shares are trading higher after the company reported better...
08-14 22:14
